Derya Kabacaoglu

TL;DR: The data indicate the clinical utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers and provide evidence for a critical dependence of mutant KRAS on SHp2 during carcinogenesis.

TL;DR: Light is shed on the recent advances in both bench and bedside investigation of immunotherapeutic options for pancreatic ductal adenocarcinoma about how PDAC adopts immune escape mechanisms, and how these mechanisms might be exploited therapeutically in combination with immune checkpoint inhibitors, such as PD-1 or CTLA-4 antibodies.

TL;DR: In mice that express oncogenic Kras in pancreatic cells, heterozygous disruption of Atg5 and reduced protein levels promotes tumor development, whereas homozygous disruptions of AtG5 blocks tumorigenesis.

TL;DR: Recent knowledge highlighting the role of Rel TFs RelA, RelB, and c-Rel in PDAC development and maintenance is discussed, providing rationales for therapeutically harnessing Rel TF function inPDAC and compiling strategies currently in (pre-)clinical evaluation.

TL;DR: While Loxl2 ablation had little effect on primary tumour development and growth, its loss significantly decreased metastasis and increased overall survival, and novel pathophysiological roles and functions for LOXL2 in PDAC are established.